• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Astrotech Reports Third Quarter of Fiscal Year 2026 Financial Results

    5/13/26 8:10:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $ASTC alert in real time by email

    AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the third quarter of fiscal year 2026, which ended March 31, 2026.

    Financial Highlights & Recent Developments

    • Research and development expense was $554 thousand, a decline of 28% from the third quarter of fiscal year 2026 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect TRACER 1000 product lines.
    • Through March 31, 2026, the Company has deployed the TRACER 1000 trace detection system in approximately 37 locations in 16 countries across the United States, Europe and Asia.



    "During the third quarter of fiscal year 2026, we remained focused on disciplined execution, achieving targeted cost-efficiency initiatives while continuing to invest selectively in the highest-return areas of the business. As a result, we are better positioned to operate efficiently in a dynamic macro environment. At the same time, our sales team is advancing a healthy sales pipeline supported by strong lead generation and ongoing customer engagement across key markets. Our deployments to date support these efforts with real-world demonstration of our solution capabilities and compelling data affirming the unique benefits of mass spectrometry technology in industrial, safety and trace detection applications. Looking ahead, we will continue to balance rigorous expense control with strategic investments to help convert pipeline opportunities into revenue growth", said Thomas B. Pickens, III, Astrotech's Chairman and Chief Executive Officer.  

    About Astrotech Corporation

    Astrotech Corporation (NASDAQ:ASTC) is an instrumentation company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech's core technology to serve specialized markets:

    • 1st Detect develops, manufactures, and markets trace detection systems for security and narcotics screening.
    • AgLAB designs process analyzers tailored to the processing of agriculture products.
    • Pro-Control produces solutions for in-situ chemical process control in industrial manufacturing.
    • EN-SCAN, Inc. delivers portable, ruggedized environmental GC-MS for on-site testing of air, water and soil.



    Astrotech is headquartered in Austin, Texas. For more information, visit www.astrotechcorp.com

    Forward-Looking Statements

    This press release contains "forward-looking statements" that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These statements may be identified by terms such as "aims," "anticipates," "believes," "contemplates," "continue," "could," "estimates," "expect," "forecast," "guidance," "intends," "may," "plans," "possible," "potential," "predicts," "preliminary," "projects," "seeks," "should," "targets," "will" or "would," or the negatives of these terms, variations of these terms or other similar expressions. These factors include, but are not limited to, the adverse impact of inflationary pressures, including significant increases in fuel costs, global economic conditions and events related to these conditions, including the ongoing wars in Ukraine and the middle east, the Company's use of proceeds from the common stock offerings, whether we can successfully complete the development of our new products and proprietary technologies, whether we can obtain the FDA and other regulatory approvals required to market our products under development in the United States or abroad, whether the market will accept our products and services and whether we are successful in identifying, completing and integrating acquisitions, as well as other risk factors and business considerations described in the Company's Securities and Exchange Commission filings including the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements in this document should be evaluated in light of these important risk factors. While we do not intend to directly harvest, manufacture, distribute or sell cannabis or cannabis products, we may be detrimentally affected by a change in enforcement by federal or state governments and we may be subject to additional risks in connection with the evolving regulatory area and associated uncertainties. Any such effects may give rise to risks and uncertainties that are currently unknown or amplify others mentioned herein. Although the Company believes the expectations reflected in its forward-looking statements are reasonable and are based on reasonable assumptions, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct. Moreover, such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. In addition, any forward- looking statements included in this press release represent the Company's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation to correct or update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    Company Contact: 

    Scott Bartley

    Interim Chief Financial Officer, Astrotech Corporation

    (512) 485-9530

    Investor Contact: 

    Matt Kreps

    Managing Director, Darrow Associates

    (214) 597-8200 mkreps@darrowir.com

    Financial tables follow



     
    ASTROTECH CORPORATION AND SUBSIDIARIES

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (In thousands, except per share data)

    (Unaudited)
     
      Three Months Ended  Nine Months Ended 
      March 31,  March 31, 
      2026  2025  2026  2025 
    Revenue $343  $534  $787  $829 
    Cost of revenue  276   297   525   428 
    Gross profit  67   237   262   401 
    Operating expenses:                
    Selling, general and administrative  2,085   2,115   5,941   5,842 
    Research and development  1,435   1,989   5,211   6,375 
    Total operating expenses  3,520   4,104   11,152   12,217 
    Loss from operations  (3,453)  (3,867)  (10,890)  (11,816)
    Other income and expense, net  (315)  234   (271)  896 
    Loss from operations before income taxes  (3,768)  (3,633)  (11,161)  (10,920)
    Net loss $(3,768) $(3,633) $(11,161) $(10,920)
    Weighted average common shares outstanding:                
    Basic and diluted  1,677   1,665   1,676   1,663 
    Basic and diluted net loss per common share:                
    Net loss per common share $(2.25) $(2.18) $(6.66) $(6.57)
    Other comprehensive loss, net of tax:                
    Net loss $(3,768) $(3,633) $(11,161) $(10,920)
    Available-for-sale securities:                
    Net unrealized gain (loss)  159   139   476   236 
    Total comprehensive loss $(3,609) $(3,494) $(10,685) $(10,684)



     
    ASTROTECH CORPORATION AND SUBSIDIARIES

    Condensed Consolidated Balance Sheets

    (In thousands, except share and per share data)
     
      March 31,  June 30, 
      2026  2025 
      (Unaudited)  (Note) 
    Assets        
    Current assets        
    Cash and cash equivalents $2,679  $3,100 
    Short-term investments  3,903   15,108 
    Accounts receivable  504   485 
    Inventory, net:        
    Raw materials  3,019   2,194 
    Work-in-process  531   425 
    Finished goods  310   310 
    Prepaid expenses and other current assets  383   353 
    Total current assets  11,329   21,975 
    Property and equipment, net  2,573   2,395 
    Intangible asset, net  50   48 
    Operating lease right-of-use assets, net  1,906   2,225 
    Other assets, net  315   346 
    Total assets $16,173  $26,989 
    Liabilities and stockholders' equity        
    Current liabilities        
    Accounts payable $234  $1,066 
    Payroll related accruals  461   529 
    Accrued expenses and other liabilities  865   451 
    Lease liabilities, current  275   405 
    Total current liabilities  1,835   2,451 
    Accrued expenses and other liabilities, net of current portion  79   164 
    Lease liabilities, net of current portion  2,104   2,274 
    Total liabilities  4,018   4,889 
    Commitments and contingencies (Note 14)        
    Stockholders' equity        
    Convertible preferred stock, $0.001 par value, 2,500,000 shares authorized; 280,898 shares of Series D issued and outstanding at March 31, 2026, and June 30, 2025  —   — 
    Common stock, $0.001 par value, 250,000,000 shares authorized at March 31, 2026, and June 30, 2025, respectively; 1,769,269 shares issued at March 31, 2026, and June 30, 2025 respectively; 1,758,953 shares outstanding at March 31, 2026, and June 30, 2025.  190,643   190,643 
    Treasury shares, 10,316 at March 31, 2026, and June 30, 2025, respectively  (119)  (119)
    Additional paid-in capital  84,050   83,310 
    Accumulated deficit  (262,030)  (250,870)
    Accumulated other comprehensive loss  (389)  (864)
    Total stockholders' equity  12,155   22,100 
    Total liabilities and stockholders' equity $16,173  $26,989 
             

    Note: The balance sheet at June 30, 2025 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by the United States generally accepted accounting principles for complete financial statements.



    Primary Logo

    Get the next $ASTC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ASTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Astrotech Corporation's 1st Detect TRACER 1000 Receives ECAC Certification for Wand Swabbing

    AUSTIN, Texas, June 08, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") announced today that its 1st Detect TRACER 1000 system has received the European Civil Aviation Conference ("ECAC") certification for wand swabbing, approved for use in screening both passengers and cargo in aviation security operations. "Wand swabbing certification extends our TRACER 1000 customer base to include airports that require wand swabbing," said Tom Pickens, Chairman and CEO of Astrotech Corporation. "We believe our technology allows for a less intrusive method of passenger testing, while also reducing bottlenecks, allowing airports to process more passengers wit

    6/8/26 8:30:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Corporation Board of Directors Approves Strategic Lunar Resource and Infrastructure Initiative to Advance Future Moon-Based Quantum Computing Manufacturing

    AUSTIN, Texas, May 27, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company"), a science and technology development company with operational spaceflight heritage, today announced that its Board of Directors has approved a strategic initiative focused on lunar resource development, autonomous lunar industrial infrastructure, and future Moon-based advanced computing and semiconductor manufacturing opportunities. The initiative is intended to position Astrotech to evaluate emerging opportunities associated with NASA's Artemis Program, the Commercial Lunar Payload Services ("CLPS") program, and next-generation commercial lunar transportation systems. Astr

    5/27/26 8:30:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EN-SCAN Launches Labrador HH-GC, Engineered to Deliver Laboratory-Grade VOC Analysis Directly in the Field

    AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- EN-SCAN, Inc. ("EN-SCAN"), a subsidiary of Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech"), today announced the commercial launch of the Labrador HH-GC, a rugged, field-portable gas chromatograph engineered to bring laboratory-grade volatile organic compound (VOC) analysis directly to the point of investigation. As environmental regulations tighten and remediation timelines compress, environmental consulting firms and industrial operators are under increasing pressure to identify contamination faster, reduce laboratory delays, and make defensible site decisions in real time. Designed specifically for environmental consultin

    5/21/26 8:30:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wilkinson Tom was granted 6,006 shares, increasing direct ownership by 25% to 29,868 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/21/26 4:16:49 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Winn Charles Arch was granted 6,006 shares, increasing direct ownership by 154% to 9,895 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/18/26 8:23:20 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Halinski John William was granted 6,006 shares, increasing direct ownership by 200% to 9,006 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/18/26 8:22:36 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    SEC Filings

    View All

    Astrotech Corporation (DE) filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - ASTROTECH Corp (0001001907) (Filer)

    6/3/26 6:01:50 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 424B5 filed by Astrotech Corporation (DE)

    424B5 - ASTROTECH Corp (0001001907) (Filer)

    6/3/26 6:01:20 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Astrotech Corporation (DE)

    10-Q - ASTROTECH Corp (0001001907) (Filer)

    5/13/26 8:30:48 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Astrotech Corporation (DE)

    SC 13D - ASTROTECH Corp (0001001907) (Subject)

    6/26/23 4:00:53 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

    SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

    2/8/23 5:29:16 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Astrotech Corporation (DE) (Amendment)

    SC 13G/A - ASTROTECH Corp (0001001907) (Subject)

    2/8/23 4:02:50 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Financials

    Live finance-specific insights

    View All

    Astrotech Announces Listing to the GSA as an Approved United States Government Vendor

    Astrotech Announces Listing to the GSA as an Approved United States Government Vendor AUSTIN, Texas, April 08, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation (1st Detect), announce that 1st Detect's TRACER 1000TM is now listed in the U.S. General Services Administration (GSA) IT Schedule 70 under Contract No. GS-35F-250GA with SRI Group LLC, Special Item Number 334290.   IT Schedule 70 is a long-term contract issued by the GSA to commercial technology vendors that allows sales to the U. S. federal government, one of the largest buyers of goods and services in the world. GSA's thoro

    4/8/24 9:00:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech to Showcase the Tracer 1000 Trace Detector at ISC West Conference

    AUSTIN, Texas, April 02, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it will be showcasing its TRACER 1000 Narcotics Trace Detector ("NTD") and Explosives Trace Detector ("ETD") at the International Security Conference and Exposition, also known as ISC West, in Las Vegas, Nevada, from April 9-12, 2024, in booth number 2067. The TRACER 1000 is a high-performance laboratory instrument that is powered by the Astrotech Mass Spectrometer Technology™ ("AMS Technology"). Our mass spectrometer is capable of rapid detection of trace levels of narcotic or explosive compounds in

    4/2/24 9:00:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Introduces the "Gold Standard" of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

     AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) ("Astrotech" or the "Company") and its wholly owned subsidiary, 1st Detect Corporation, announces that it is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (NTD). The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds. Currently, the Company's Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world. The NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo,

    3/25/24 9:00:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Leadership Updates

    Live Leadership Updates

    View All

    Astrotech Reports Second Quarter of Fiscal Year 2026 Financial Results

    AUSTIN, Texas, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") reported its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025. Financial Highlights & Recent Developments Research and development expense was $1,832 thousand, a decline of 25% from the second quarter of fiscal year 2025 as the Company transitions from development stage to saleable products for its EN-SCAN Handheld GC and 1st Detect Tracer 1000 product lines.Through December 31, 2025, the Company has deployed the TRACER 1000 trace detection system in approximately 35 locations in 16 countries across the United States, Europe and As

    2/13/26 8:15:00 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Subsidiary 1st Detect Appoints Industry Veteran David Spada as Director of Global Sales to Expand Global Reach of TRACER 1000™

    AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or "Astrotech") today announced that its subsidiary, 1st Detect Corporation ("1st Detect"), has appointed industry veteran, David Spada, as Director of Global Sales. This strategic hire strengthens 1st Detect's commercial leadership as the company scales deployment of its TRACER 1000™ mass spectrometry-based explosives and narcotics trace detector across international security markets. Mr. Spada brings over a decade of specialized trace detection experience to the 1st Detect team. Throughout his career at Implant Sciences, Morpho Detection, and Rapiscan Systems, Mr. Spada has held position

    1/21/26 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Astrotech Corporation Appoints Scott Bartley as Interim Chief Financial Officer

    AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Astrotech Corporation (NASDAQ:ASTC) (the "Company" or ("Astrotech"), today announced that it has appointed Scott Bartley as Interim Chief Financial Officer ("CFO") of the Company, effective as of October 20, 2025. "We are pleased to announce Scott Bartley as Chief Financial Officer," stated Thomas B. Pickens III, Chairman and Chief Executive Officer of Astrotech Corporation. "He brings over two decades of expertise as a Controller and CFO, across multiple industries, providing important qualification and vantage points for our business across multiple end markets."​Mr. Bartley, age 56, has served as a financial consultant since 2011, inclu

    10/31/25 4:15:00 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ASTC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Becker James Frank bought $19,675 worth of shares (2,034 units at $9.67), increasing direct ownership by 14% to 16,121 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/30/24 9:16:58 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Hinojosa Jaime bought $8,541 worth of shares (900 units at $9.49), increasing direct ownership by 13% to 7,881 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/28/24 9:46:54 AM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Wilkinson Thomas Wiley bought $10,536 worth of shares (1,109 units at $9.50), increasing direct ownership by 6% to 20,862 units (SEC Form 4)

    4 - ASTROTECH Corp (0001001907) (Issuer)

    5/21/24 12:54:36 PM ET
    $ASTC
    Biotechnology: Laboratory Analytical Instruments
    Industrials